Allos Provides New Folotyn Data (NASDAQ:ALTH)

Allos Therapeutics Inc (NASDAQ:ALTH) has reported a new analysis of data from the pivotal PROPEL trial of FOLOTYN in patients who are suffering from relapsed and refractory peripheral T-cell lymphoma (PTCL). As per the new data provided by Allos Therapeutics, FOLOTYN may be a potential treatment option for patients who have progressed after receiving a prior autologous SCT and may also be a potential bridge to an autologous or allogeneic SCT following response to FOLOTYN therapy. These data were presented during a poster session at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA.

Allos Therapeutics, Inc. is one of the leading biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also exploring the potential of FOLOTYN in other indications. Additionally, the data demonstrated that promising results were observed in patients who responded to treatment with FOLOTYN and proceeded to receive SCT as initial subsequent therapy. Of the 109 patients evaluable for response, 6 proceeded to SCT after responding to FOLOTYN. Thus, responses to FOLOTYN permitted patients to proceed to a potential curative transplant option. This analysis also underscores the important role FOLOTYN for PTCL patients who have failed to respond to prior therapies, progressed after prior autologous stem cell transplant and as a bridge to stem cell transplant for patients who respond to FOLOTYN therapy.